Cholangiocarcinoma (CCA) is a highly lethal adenocarcinoma of the hepatobiliary system,
which can be classified as intrahepatic, perihilar and distal. Each anatomic subtype has …

Cancer-associated fibroblasts (CAFs) are central players in the microenvironment of solid
tumors, affecting cancer progression and metastasis. CAFs have diverse phenotypes …

Background Alterations in fibroblast growth factor receptor 2 (FGFR2) have emerged as
promising drug targets for intrahepatic cholangiocarcinoma, a rare cancer with a poor …

Importance Isocitrate dehydrogenase 1 (IDH1) variations occur in up to approximately 20%
of patients with intrahepatic cholangiocarcinoma. In the ClarIDHy trial, progression-free …

Biliary tract cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up☆ -
Annals of Oncology Skip to Main Content Advertisement Annals of Oncology European Society …

Background Treatment options are sparse for patients with advanced cholangiocarcinoma
after progression on first-line gemcitabine-based therapy. FGFR2 fusions or rearrangements …

Immunotherapy has made remarkable strides in cancer therapy over the past decade.
However, such emerging therapy still suffers from the low response rates and immune …

Background & Aims Cholangiocarcinoma (CCA) is a rare and heterogeneous biliary cancer,
whose incidence and related mortality is increasing. This study investigates the clinical …

We performed proteogenomic characterization of intrahepatic cholangiocarcinoma (iCCA)
using paired tumor and adjacent liver tissues from 262 patients. Integrated proteogenomic …

Mutations in the genes encoding the cytoplasmic and mitochondrial forms of isocitrate
dehydrogenase (IDH1 and IDH2, respectively; collectively referred to as IDH) are frequently …